BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates

Core Insights - BridgeBio Pharma, Inc. reported strong financial results for Q4 and full year 2025, with total revenues of $154.2 million for Q4 and $502.1 million for the full year, primarily driven by net product revenue from Attruby [4][15] - The company achieved three positive Phase 3 trial readouts in a short span, indicating robust progress in its drug development pipeline [4][6] - Attruby has established itself as a leading therapy for ATTR-CM, demonstrating significant clinical benefits and achieving 7,804 unique patient prescriptions as of February 20, 2026 [5][6] Financial Performance - Total revenues for Q4 2025 were $154.2 million, a substantial increase from $5.9 million in Q4 2024, driven by a $143.1 million increase in net product revenue from Attruby [14] - For the full year 2025, total revenues reached $502.1 million, up from $221.9 million in 2024, primarily due to a $359.5 million increase in net product revenue from Attruby [15] - The company reported a net loss attributable to common stockholders of $192.9 million for Q4 2025 and $724.9 million for the full year, compared to losses of $265.1 million and $535.8 million in the prior year [23][24] Pipeline Overview - BridgeBio's pipeline includes several promising candidates: - Acoramidis for ATTR is approved in multiple regions, with new data expected at upcoming scientific sessions [2] - BBP-418 for LGMD2I/R9 has shown positive interim results and is on track for NDA submission in 1H 2026 [2] - Encaleret for ADH1 has also achieved positive Phase 3 results, with NDA submission planned for 1H 2026 [2] - Infigratinib for achondroplasia has met its primary endpoint in Phase 3 trials, with NDA submission anticipated in 2H 2026 [2] Commercial Updates - Attruby has shown a 35% quarter-over-quarter growth in net product revenue in Q4 2025, reflecting its strong market position as a near-complete TTR stabilizer [6] - The company has successfully established a commercial presence with 1,856 unique prescribers for Attruby, indicating broad acceptance in the medical community [5][6] - BridgeBio is preparing for the potential launches of BBP-418, encaleret, and infigratinib, which could lead to a total of six approved medicines by the end of its first decade [6] Corporate Updates - As of December 31, 2025, BridgeBio had $587.5 million in cash, cash equivalents, and marketable securities, down from $681.1 million in the previous year [11] - The company completed the issuance of $632.5 million in convertible notes in January 2026, enhancing its financial position to support ongoing operations [4][7] - BridgeBio's unique model for sustainable drug development has been highlighted in peer-reviewed publications, emphasizing its ability to reduce risks and improve clinical success rates [7]